ARGX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.28B

+69.63%

5.736

+673.9%

1.29B

+61.6%

6.547

+156.54%

1.38B

+43.04%

7.092

+90.69%

Estimates Revision

The market is revising Upward the revenue expectations for argenx SE (ARGX) for FY2025, with the revenue forecasts being adjusted by 6.4% over the past three months. During the same period, the stock price has changed by -1.06%.

Revenue Estimates for FY2025

Revise Upward

+6.4%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+15.2%

In Past 3 Month

Stock Price

Go Down

-1.06%

In Past 3 Month

21 Analyst Rating

Wall Street analysts forecast ARGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARGX is 956.06 USD with a low forecast of 780.00 USD and a high forecast of 1146 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

20 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

780.00

Averages

956.06

High

1146

Current: 0.000

Low

780.00

Averages

956.06

High

1146

Morgan Stanley

Sean Laaman

Overweight

maintain

2026-01-08

New

Reason

Morgan Stanley

Sean Laaman

Price Target

2026-01-08

New

maintain

Overweight

Reason

Morgan Stanley analyst Sean Laaman raised the firm's price target on Argenx to $1,160 from $1,110 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

Truist

Danielle Brill

Buy

maintain

$950

2026-01-08

New

Reason

Truist

Danielle Brill

Price Target

$950

2026-01-08

New

maintain

Buy

Reason

Truist analyst Danielle Brill raised the firm's price target on Argenx to $1,030 from $950 and keeps a Buy rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.

Citi

Samantha Semenkow

Buy

downgrade

2026-01-08

New

Reason

Citi

Samantha Semenkow

Price Target

2026-01-08

New

downgrade

Buy

Reason

Citi analyst Samantha Semenkow lowered the firm's price target on Argenx to $1,091 from $1,124 and keeps a Buy rating on the shares. The firm says its neurologist survey shows the Vyvgart launch continues to gain momentum. Citi says Argenx is a top pick for 2026. The target drop reflects a model update.

Wolfe Research

Peer Perform -> Outperform

upgrade

$50

2026-01-06

New

Reason

Wolfe Research

Price Target

$50

2026-01-06

New

upgrade

Peer Perform -> Outperform

Reason

As previously reported, Wolfe Research upgraded Immunovant (IMVT) to Outperform from Peer Perform with a $50 price target. While Graves' may be an attractive market, the firm had believed re-rating would take years. However, with Argenx (ARGX) now participating in Graves' and thus investors developing higher appreciation, there likely is now a higher valuation floor to Immunovant, the analyst contends. The firm sees the declining short float as supporting evidence for this and notes that the company is moving closer to two positively-skewed catalysts in 2026.

Barclays

NULL -> Overweight

maintain

2026-01-06

New

Reason

Barclays

Price Target

2026-01-06

New

maintain

NULL -> Overweight

Reason

Barclays raised the firm's price target on Argenx to EUR 880 from EUR 850 and keeps an Overweight rating on the shares.

Guggenheim

Yatin Suneja

maintain

2025-12-18

Reason

Guggenheim

Yatin Suneja

Price Target

2025-12-18

maintain

Reason

Guggenheim analyst Yatin Suneja raised the firm's price target on Argenx to $1,160 from $1,085 and keeps a Buy rating on the shares. The firm is removing sales for TED from its model following the recent Vyvgart setback in TED, while increasing its peak sales estimates in gMG to $6.7B from a previous $5.7B and to $4.96B from a previous $4.7B in CIDP, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for argenx SE (ARGX.O) is 33.32, compared to its 5-year average forward P/E of -71.61. For a more detailed relative valuation and DCF analysis to assess argenx SE 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-71.61

Current PE

33.32

Overvalued PE

142.63

Undervalued PE

-285.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-9.32

Current EV/EBITDA

25.83

Overvalued EV/EBITDA

93.99

Undervalued EV/EBITDA

-112.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

26.45

Current PS

9.55

Overvalued PS

45.31

Undervalued PS

7.59

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ARGX News & Events

Events Timeline

No data

News

2.0

01-06Benzinga

AbbVie Upgraded Price Target to $269 Despite 4% Stock Drop

1.0

01-06Globenewswire

argenx CEO Tim Van Hauwermeiren to Present at J.P. Morgan Healthcare Conference on January 12, 2026

5.0

01-05Globenewswire

argenx Transitions CEO Role to Karen Massey, Tim Van Hauwermeiren Becomes Chairman

People Also Watch

Frequently Asked Questions

What is argenx SE (ARGX) stock price today?

The current price of ARGX is 788.49 USD — it has decreased -0.89 % in the last trading day.

What is argenx SE (ARGX)'s business?

argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.

What is the price predicton of ARGX Stock?

What is argenx SE (ARGX)'s revenue for the last quarter?

argenx SE revenue for the last quarter amounts to 1.13B USD, increased 96.60 % YoY.

What is argenx SE (ARGX)'s earnings per share (EPS) for the last quarter?

argenx SE. EPS for the last quarter amounts to 5.18 USD, increased 272.66 % YoY.

What changes have occurred in the market's expectations for argenx SE (ARGX)'s fundamentals?

How many employees does argenx SE (ARGX). have?

argenx SE (ARGX) has 1599 emplpoyees as of January 10 2026.

What is argenx SE (ARGX) market cap?

Today ARGX has the market capitalization of 48.55B USD.